February 1, 2019Open Access

Late-onset Alzheimer Disease

Key Points

Key points are not available for this paper at this time.

Abstract

AD is very common in older neurologic patients. Neurologists should set the standard for the diagnosis and care of patients with AD and should be familiar with emerging biomarkers that have transformed AD research and are primed to enter the clinical arena.

AIに質問

Bookmark

View Full Paper

Cite This Study

Gil D. Rabinovici (Fri,) studied this question.

synapsesocial.com/papers/69deb895c3a6346e97e93b4a https://doi.org/https://doi.org/10.1212/con.0000000000000700

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study2010 · 215 citations
2Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy2013 · 3,506 citations
3SPECT Perfusion Imaging in the Diagnosis of Dementia1995 · 24 citations
4Association of traumatic brain injury with subsequent neurological and psychiatric disease: a meta-analysis2015 · 440 citations
5Practice guideline update summary: Mild cognitive impairment [RETIRED]2017 · 2,184 citations

AIに質問

Bookmark

View Full Paper